Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease. In this landscape, the innovative treatment with PARP inhibitors (PARPis) demonstrated an outstanding activity in EOC, and is currently changing clinical practice in BRCA mutant patients.

PARP Inhibitors in Ovarian Cancer

Ghisoni, Eleonora;Giannone, Gaia;Aglietta, Massimo;Sapino, Anna;Valabrega, Giorgio
Last
2018-01-01

Abstract

Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease. In this landscape, the innovative treatment with PARP inhibitors (PARPis) demonstrated an outstanding activity in EOC, and is currently changing clinical practice in BRCA mutant patients.
2018
13
392
410
Ovarian cancer; PARP inhibitors; niraparib; olaparib; recent patents; rucaparib; talazoparib; veliparib
Mittica, Gloria; Ghisoni, Eleonora; Giannone, Gaia; Genta, Sofia; Aglietta, Massimo; Sapino, Anna; Valabrega, Giorgio
File in questo prodotto:
File Dimensione Formato  
PARP inhibitors in ovarian cancer_Valabrega.pdf

Accesso aperto

Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 796.82 kB
Formato Adobe PDF
796.82 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1742207
Citazioni
  • ???jsp.display-item.citation.pmc??? 72
  • Scopus 106
  • ???jsp.display-item.citation.isi??? 104
social impact